# Nuclide Therapeutics

Source: https://onco.cc/companies/nuclide-therapeutics/  
OnCo record `nuclide-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Nuclide Therapeutics is a UK start-up developing radioactive drugs for cancers that have stopped responding to other treatments. Its lead medicine carries radioactive iodine and was moving towards first human trials in 2026.

## Summary

Nuclide Therapeutics is a UK company co-founded by Muhammet Tanç (CEO), Tim Witney (CSO), Sofia Santos (COO) and Richard Edwards (CTO), developing targeted radiotheranostics for therapy-resistant solid tumours. Its lead therapeutic, NTx-11, is labelled with iodine-131. The company announced a GBP 5 million investment in September 2025 to fund first-in-human trials, and an October 2025 release describes it as a milestone-based first investment round funded by Marathon Beteiligungs AG. Its pipeline lists NTx-010, NTx-011 and NTx-043 across diagnostic and therapeutic uses, from discovery to phase 0/1. In 2026 it announced a discovery collaboration using Enamine's platform and a co-development agreement with pharmAI, and Chemical & Engineering News named it one of ten start-ups to watch.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Nuclide Tx
- HQ: London
- Type: radiopharma
- Website: https://nuclidetx.com/

## Notes

- Founding year not stated by the company; third-party profiles say it was founded in 2024 as a spin-out of Tim Witney's lab at King's College London. Third-party sources name ALDH1A1 as the lead target, but the company site does not, so no target is linked. The website gives no city; London is from the Enamine release dateline and trade directories.

## Sources

- Official website: https://nuclidetx.com/
- Launch announcement: https://nuclidetx.com/news/launch-announcement
- Funding round press release: https://nuclidetx.com/news/latest-press-release
- Enamine collaboration release: https://enamine.net/news-press-releases/press-releases/enamines-idd-platform-accelerates-nuclide-therapeutics-precision-radiotheranostics-pipeline-towards-the-clinic

## Connected records

- fronts: [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- technologies: [Radioiodine therapy and whole-body iodine scanning](https://onco.cc/technologies/radioiodine-therapy/), [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/)

---
JSON: https://onco.cc/api/v1/entities/nuclide-therapeutics.json